#Circulating Tumor Dna


Dr. Shirasu on the Utilization of ctDNA Testing in CRC

Hiromichi Shirasu, MD, discusses the utilization of circulating tumor DNA testing in colorectal cancer. Hiromichi Shirasu, MD, senior staff member, Division of Clinical Oncology, Shizuoka Cancer Center, Shizuoka, Japan, discusses the utilization of circulating tumor DNA (ctDNA) testing in colorectal cancer (CRC). The GALAXY trial (UMIN000039205), part of the CIRCULATE-Japan...

Tebentafusp for Uveal Melanoma: Assessing Treatment Response

Richard D. Carvajal, MD, Columbia University Irving Medical Center, Marlana M. Orloff, MD, Thomas Jefferson University Hospital. Considerations for accurately predicting and identifying response to tebentafusp in uveal melanoma, and insight regarding the appropriate length of treatment for patients with disease progression. Richard D. Carvajal, MD: You're right, this is...
Picture for Tebentafusp for Uveal Melanoma: Assessing Treatment Response

Foresight Diagnostics’ PhasED-Seq detects circulating tumor DNA at extremely low levels

Foresight Diagnostics Inc. has developed a circulating tumor DNA (ctDNA) detection platform for detecting minimal residual disease (MRD) in B-cell lymphomas, a form of non-Hodgkin lymphoma and the most common lymphoma in the U.S., accounting for about 85% of all cases. Now, it has published data showing its phased variant enrichment detection sequencing (PhasED-Seq) nearly doubled the identification of patients with aggressive lymphoma who were not cured by standard therapy and need new treatment options.
Picture for Foresight Diagnostics’ PhasED-Seq detects circulating tumor DNA at extremely low levels

Evaluating the IMpower133 Trial of Atezolizumab for Patients with ES-SCLC

Case-Based Roundtable Meetings Spotlight, Case-Based Roundtable Meetings Spotlight July 1 2021,. During a Targeted Oncology Case-Based Roundtable event, Balazs Halmos, MD, MS, discussed the case of a 73-year-old patient with early-stage small cell lung cancer. During a Targeted Oncology Case-Based Roundtable event, Balazs Halmos, MD, MS, discussed the case of...

Following Cancer Progress in Real Time

HOUSTON – University of Houston engineering researcher Wei-Chuan Shih has been awarded $2.7 million from the National Institute of Biomedical Imaging and Bioengineering to detect cancer biomarkers in blood by counting exosomes. Known as “liquid biopsy,” the process, which requires only a simple blood draw, can improve the accuracy of measuring nearly invisible minimal residual disease (MRD) in cancer tumors.

DLBCL: Approaching CNS Prophylaxis

John P. Leonard, MD, Weill Cornell Medicine, Cyrus Khan, MD, West Penn Hospital , Loretta J. Nastoupil, MD, University of Texas MD Anderson Cancer Center, Greg Nowakowski, MD, Mayo Clinic , David Rizzieri, MD, Duke Health. A panel of experts explain how they approach CNS prophylaxis in DLBCL. John Leonard,...

Dr. Shirasu on the Design for the GALAXY Trial Examining ctDNA in CRC

Hiromichi Shirasu, MD, discusses the design of the GALAXY trial, part of the CIRCULATE-Japan project, which is examining circulating tumor DNA in patients with resectable colorectal cancer. Hiromichi Shirasu, MD, of the Shizuoka Cancer Center in Shizuoka, Japan, discusses the design of the GALAXY trial (UMIN000039205), part of the CIRCULATE-Japan...
CancerMedscape News

ctDNA Identifies Patients Who Benefit From Immunotherapy in MIUC

Among patients with muscle-invasive urothelial carcinoma (MIUC), the presence of detectable circulating tumor DNA (ctDNA) after surgery may identify those who are likely to benefit from adjuvant immunotherapy with the immune checkpoint inhibitor atezolizumab (Tecentriq). The finding comes from a new analysis of data from the ImVigor010 trial, which had...

Implications of PIK3CA Mutations in HR+ mBC

Andrew D. Seidman, MD, Memorial Sloan Kettering Cancer Center, Aditya Bardia, MD, Massachusetts General Hospital Cancer Center, Dejan Juric, MD, Massachusetts General Hospital, Nicholas McAndrew, MD, MSCE, UCLA Health, Hope S. Rugo, MD, FASCO, UCSF Helen Diller Family Comprehensive Cancer Center. Dejan Juric, MD, leads the discussion on the role...

Circulating tumor DNA

This study states that HIV is an exclusion criterion for most lung cancer (LC) trials, however LC is the most common non-AIDS-defined malignancy in people living with HIV (PLHIV), poorer prognosis than the general population. Circulating tumor DNA (ctDNA) was a prognostic marker in LC patients from the general population. This study assessed ctDNA’s prognostic value in PLHIV from a dedicated phase II trial. Overall, 61 PLHIV with advanced non-squamous non-small-cell lung cancer (NSCLC) participated in the IFCT Phase II trial evaluating first-line four-cycle carboplatin (Ca) AUC5 pemetrexed (P) 500 mg/m2 induction therapy every 3 weeks, followed by P maintenance therapy. Blood samples collected before treatment were analyzed to detect ctDNA using ultra-deep targeted next-generation-sequencing (NGS). Appropriate samples were available from 55 PLVIH and analyzed for ctDNA detection. Including 42 males (76.4 %), 52.9 years median age, 51 smokers (92.7 %), five with non-squamous NSCLC Stage III (9%), 50 Stage IV (91 %), and performance status (PS) 0−2. ctDNA was detected in 35 patients (64 %), 22 with high and 13 with low ctDNA levels.

Natera Inks Distribution Deal With TomaLab for Italy

NEW YORK — TomaLab said on Tuesday that it has signed an agreement with Natera to distribute three of that firm's cell-free DNA tests in Italy. Under the terms of the deal, Busto Arsizio, Italy-based TomaLab will distribute Natera's Panorama noninvasive prenatal test, Signatera circulating tumor DNA test for cancer treatment monitoring and minimal residual disease assessment, and Prospera test for assessing transplant rejection.

Human Blood Harbors Cell-Free Microbial DNA

Most biomarkers that clinicians use to diagnose cancer are human. But growing evidence for a link between the microbiome and malignancy presents an opportunity to look at the presence of microbial DNA as a way to identify and possibly predict disease. In a study published June 23 in Genome Biology, researchers demonstrate that it is possible to detect bacterial DNA in blood samples in both healthy people and melanoma patients.

Liquid Biopsy Has Potential to Advance Precision Medicine in Melanoma

Years of research has shown that in cancers like melanoma, liquid biopsy enables the detection of biomarkers, such as circulating tumor cells, circulating tumor DNA, and exomes. Precision medicine has opened the door to more personalized treatments in melanoma, improving the odds of survival for patients with advanced stage of...

Phase 3 Trial Investigating Adagrasib Plus Cetuximab in KRAS G12C-Mutated CRC

The phase 3 KRYSTAL-10 trial continues to look at the combination of adagrasib and cetuximab in patients with previously treated advanced colorectal cancer and a KRAS G12C mutation in their tumor. The global, open-label, randomized phase 3 KRYSTAL-10 study (NCT04793958) is currently looking at the efficacy and safety of the...